RESMED INC
NYSE: RMD·San Diego, California·CIK 0000943819
- Price
- $238.19
- Base IV
- $188.90
Valuation snapshot
At $238.19, the price sits between our base case ($188.90) and bull case ($244.52).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $188.90
- 79% of the price · range $132.71–$244.52
- Price vs base case
- 26% above
- $238.19 against $188.90
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $132.71 to bull $244.52. Values per share.
Price against each value
- Bear case
- $132.71
- Price 79% above
- No growth
- …
- —
- Base case
- $188.90
- Price 26% above
What does Resmed do?
ResMed provides medical devices and software for sleep and breathing disorders, such as CPAP machines for obstructive sleep apnea, to help patients manage chronic conditions and clinicians monitor care.
It brought in $5.7B of sales in the 12 months to Sep 2026.
Led by Michael (Mick) Farrell, Chairman of the Board and Chief Executive Officer since 2013. ResMed Inc. Definitive Proxy Statement (DEF 14A), 2026 Annual Meeting – Executive Officers
- Industry
- Healthcare
- Based in
- San Diego, California
- Trades on
- NYSE as RMD
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 28¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 39¢ of every dollar.
- Making what it sells39¢
- Research and development7¢
- Sales, marketing and admin20¢
- Everything else it takes to operate1¢
- Tax7¢
- Left as profit28¢
- Interest and other income came back in+2¢
Who pays Resmed, and for what?
Resmed sells connected devices and related products that help treat sleep and breathing conditions, including sleep apnea. It also provides diagnostic services and cloud software for patients and healthcare providers, earning revenue from product sales and software and service offerings.
Healthcare providers, equipment suppliers, hospitals, insurers and, through some home healthcare businesses, patients buy or pay for Resmed’s products and services.
Devices
51%CPAP and other breathing devices, including ventilation equipment.
ResMed AirSense 11 CPAP deviceImage: Resmed Masks and other
37%Masks, diagnostic products, accessories and other sleep and breathing health products.
Residential Care Software
12%Software and services that help residential care providers manage billing, records, operations and patient engagement.
Where its work physically happens, beyond headquarters:
- Sydney manufacturing and R&D campus — Sydney, Australia. ResMed’s owned Sydney site combines manufacturing with its primary research and development facilities, making it central to product supply and development.
- Tuas manufacturing facility — Singapore, Singapore. Tuas is a main manufacturing facility for ResMed-branded products, supporting the scale and resilience of its global supply network.
- Atlanta manufacturing and distribution facility — Atlanta, United States. This 467,000-square-foot facility manufactures ResMed-branded products and provides warehousing and distribution capacity.
- Johor Bahru manufacturing facility — Johor Bahru, Malaysia. This 349,000-square-foot site is a main ResMed-branded manufacturing facility with engineering and research and development functions.
- Calabasas manufacturing facility — Calabasas, United States. ResMed identifies Calabasas as a main ResMed-branded manufacturing site and states that operations transitioned there from Chatsworth during fiscal 2027.
How is the business doing?
Sales grew from $3.2B in 2021 to $5.7B in 2026, about 12% a year.
Running the business leaves about 33¢ of each sales dollar as operating profit, up from 28¢ in 2021.
After paying for its upkeep and new investment, it had $1.6B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Resmed says its mission is to help people sleep better, breathe better and live higher-quality lives with healthcare delivered at home.
“helping people sleep better, breathe better, and live higher-quality lives”
Who is responsible for the plan?
- Michael (Mick) FarrellChairman of the Board and Chief Executive Officer
Leads ResMed as chief executive officer and chairs its board of directors. As CEO he oversees the whole company, which sells sleep and breathing devices, masks and accessories, along with residential care software.
- Justin LeongChief Product Officer
Oversees product management, hardware and software engineering, AI product engineering and data science, and product strategy. His product and engineering group develops the connected devices, masks and software that ResMed sells.
Roles checked November 13, 2026.
What management says it is working on now:
Grow sleep apnea care
Management plans to improve its sleep apnea products and make screening, diagnosis and starting treatment simpler.
Resmed Inc. 2026 Form 10-KExpand awareness and access
The company says it is educating the public and healthcare professionals about sleep apnea, COPD and other conditions, and building partnerships that can guide people toward assessment and care.
Resmed Inc. 2026 Form 10-KDevelop adjacent therapies
Resmed is expanding into related sleep and breathing needs, including restless legs syndrome through its Noctrix acquisition, and continuing to develop breathing health products.
Resmed Inc. 2026 Form 10-KBuild connected home healthcare
Management describes cloud-connected devices and software as central to its strategy, using remote monitoring and patient tools to support care at home.
Resmed Inc. 2026 Form 10-KFocus the portfolio
Resmed agreed to sell MatrixCare as part of its plan to focus on sleep, breathing and connected home-based healthcare.
Resmed Inc. 2026 Form 10-K
- Residential Care Software revenue growth, Fiscal year 2027
- High single-digit growth
- Resmed Q4 FY2026 Earnings Call Transcript
- Capital returned to shareholders, Fiscal year 2027
- More than $1.85 billion
- Resmed FY2026 Results Release
What's changing right now?
Growth is slowing. In Q1 2027 it sold 6% more than a year earlier. The year before, quarters averaged 10%.
Its operating margin is narrower than a year ago: 32¢ per sales dollar, against 33¢.
Since Oct 2026 the share price has fallen 6%, from $252.83 to $238.19.
Recently
October 29, 2026
GAAP operating margin, quarterly changed to 32.0%
Resmed Q1 FY27 earnings releaseOctober 29, 2026
Reported revenue growth, quarterly year over year changed to 5.9%
Resmed Q1 FY27 earnings releaseSeptember 30, 2026
Quarterly Year-over-Year Revenue Growth changed to 5.9%
ResMed Q1 FY2027 Earnings Release
Coming up
Expected around September 1, 2026, in the first quarter of fiscal year 2027
MatrixCare sale
Resmed expects to complete its agreed sale of MatrixCare, subject to regulatory approvals and closing adjustments.
Resmed Q4 FY2026 Earnings Call TranscriptOctober 29, 2026
First quarter fiscal 2027 earnings call
Resmed is scheduled to report its first quarter fiscal 2027 results.
Resmed Investor Relations
Our own estimate moved too: the base case went from $212.97 to $188.90 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Competing treatments and technology
New devices, software or medicines could offer better results or value, reduce demand for Resmed products, or pressure the prices it can charge.
From the company's own filingsWould hit how fast sales growResmed Inc. 2026 Form 10-K
Coverage and reimbursement
Insurers or government programs may limit coverage or payment for products and services. Lower reimbursement can make customers less able or willing to buy.
From the company's own filingsWould hit how fast sales growResmed Inc. 2026 Form 10-K
Supply disruptions and trade costs
Shortages of components, shipping problems or new tariffs could raise costs or prevent Resmed from making enough products to meet demand.
From the company's own filingsWould hit how much of each sale it keepsResmed Inc. 2026 Form 10-K
Product safety and regulatory requirements
If products do not meet safety or quality requirements, Resmed could face recalls, sales delays, legal costs or damage to its reputation.
From the company's own filingsWould hit how fast sales growResmed Inc. 2026 Form 10-K
Acquisition and divestiture execution
Resmed may not integrate acquired businesses successfully or complete strategic changes as expected. The company also faces risks as it moves to sell MatrixCare.
From the company's own filingsWould hit how fast sales growResmed Inc. 2026 Form 10-K
Health data and software security
A cyberattack, service outage or failure to protect health information could disrupt software services, lead to legal or regulatory action, and harm customer trust.
From the company's own filingsWould hit how fast sales growResmed Inc. 2026 Form 10-K
Q1 FY27 reported growth of 5.9% was below the roughly 10% average of FY24–FY26, which shows a slowdown.
From our researchWould hit how fast sales growResmed Q1 FY27 earnings release
The $340M Noctrix acquisition shows that acquisition spending can push reinvestment up in some years.
From our researchWould hit how much it has to reinvestResmed completes Noctrix acquisition
Is it a good business?
From 2016 to 2026 it earned between 15% and 26% on the capital invested in it, a median of 20%. Its cost of capital in the latest valuation is 8.6%; returns were above it in every one of the 10 years.
From 2016 to 2026 it earned between 15% and 25% on its shareholders' equity, a median of 21%.
Over 10 years its operating margin ranged from 22¢ to 33¢ per sales dollar, a median of 28¢. Gross margin ran from 56¢ to 61¢.
Cost of capital 8.6%
It bought back shares: the count fell 2.4% in a year, so each remaining share owns a slightly bigger slice.
It holds $601.1M more in cash than it owes.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $238.19. Our put its value between $132.71 and $244.52, with $188.90 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $132.71
In this scenario ResMed's growth, which slowed to about 6% last quarter, keeps fading to around 3–4% a year as new weight-loss drugs and competition limit new sleep-apnea patients, and profits slip slightly from today's level.
Base case, $188.90
In this scenario ResMed returns to the steady mid-to-high single-digit growth management is guiding for, after selling a software unit, and keeps its profitability around today's strong level.
Bull case, $244.52
In this scenario ResMed gets back to the roughly 10% yearly growth it delivered in recent years, as more people are diagnosed with sleep apnea and new products add sales, while profitability edges higher.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 26%
For Resmed to be worth today's $238.19, sales would need to grow about 11.2% a year. We assume 5.7%. Over the last 5 years, sales grew 11.4% a year.
Or, if sales grow 5.7% as we assume, the price works with a profit margin of 43.1% (we assume 34.0%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 11.2% a year?
Try your own numbersWe're moderately sure of this range: it scores 72 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $188.90 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.7%
- Operating margin34.0%
- Long-term growth rate3.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$188.90 -20.7%


